SynthesisAsian Pacific journal of cancer prevention : APJCP2026
From Radiation to Immune Response: A Systematic Review of Systemic Immunomodulation in Squamous Cell Head and Neck Cancer.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is frequently treated with radiotherapy (RT), often combined with chemotherapy. Beyond local tumor control, RT induces systemic immunomodulatory effects. This systematic review evaluates alterations in peripheral immune cell subpopulations and circulating biomarkers in HNSCC patients undergoing RT with or without chemotherapy.
methodsA systematic search across five databases identified 12 eligible studies. Inclusion criteria encompassed adult patients with HNSCC treated with external beam RT and analysis of immune parameters in peripheral blood. The review protocol was registered in the Prospective Register of Systematic Reviews (PROSPERO, registration number CRD42021283028).
resultsRT induced lymphopenia, with consistent reductions in T, B, and dendritic cells, and increases in regulatory T cells (Tregs). Altered expression of immune activation markers (such as CD69 and HLA-DR) and exhaustion markers (such as PD-1 and CTLA-4) was noted. Gene expression of FDXR, GADD45, and others demonstrated sustained modulation post-RT. Changes in cytokines, adhesion molecules (CX3CR1, CD11a), and immune checkpoint proteins (PD-L1) were associated with treatment response and toxicity. Baseline immune profiles correlated with the risk of acute toxicity.
conclusionRT, either alone or in combined with chemotherapy, significantly alters systemic immunity in HNSCC. Immunophenotyping and peripheral biomarkers show prognostic potential, supporting their integration into personalized treatment strategies. However, standardized, large-scale longitudinal studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.